GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sophiris Bio Inc (OTCPK:SPHS) » Definitions » Shares Outstanding (EOP)

Sophiris Bio (Sophiris Bio) Shares Outstanding (EOP) : 33.57 Mil (As of Sep. 2019)


View and export this data going back to 2013. Start your Free Trial

What is Sophiris Bio Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Sophiris Bio's shares outstanding for the quarter that ended in Sep. 2019 was 33.57 Mil.

Sophiris Bio's quarterly shares outstanding increased from Jun. 2019 (30.22 Mil) to Sep. 2019 (33.57 Mil). It means Sophiris Bio issued new shares from Jun. 2019 to Sep. 2019 .

Sophiris Bio's annual shares outstanding increased from Dec. 2017 (30.11 Mil) to Dec. 2018 (30.21 Mil). It means Sophiris Bio issued new shares from Dec. 2017 to Dec. 2018 .


Sophiris Bio Shares Outstanding (EOP) Historical Data

The historical data trend for Sophiris Bio's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sophiris Bio Shares Outstanding (EOP) Chart

Sophiris Bio Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.84 17.24 30.11 30.11 30.21

Sophiris Bio Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.11 30.21 30.21 30.22 33.57

Competitive Comparison of Sophiris Bio's Shares Outstanding (EOP)

For the Biotechnology subindustry, Sophiris Bio's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sophiris Bio's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sophiris Bio's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Sophiris Bio's Shares Outstanding (EOP) falls into.



Sophiris Bio Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Sophiris Bio  (OTCPK:SPHS) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Sophiris Bio Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Sophiris Bio's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Sophiris Bio (Sophiris Bio) Business Description

Traded in Other Exchanges
N/A
Address
1258 Prospect Street, La Jolla, CA, USA, 92037
Sophiris Bio Inc is a clinical-stage biopharmaceutical company. It focuses on the development of products for the treatment of urological diseases. The company's product portfolio includes topsalysin (PRX302), for the treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. Topsalysin is a genetically modified recombinant protein which is selectively activated by enzymatically active prostate-specific antigen (PSA), which is only present in the prostate, leading to localized cell death and tissue disruption without damage to neighboring tissue and nerves. Geographically all the operations of the company are functioned in the United States.
Executives
Randall E Woods director, officer: President & Chief Exec Officer C/O ARENA PHARMACEUTICALS, INC. 6166 NANCY RIDGE DRIVE SAN DIEGO CA 92121
Lars Ekman director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
James L Heppell director
Gerald T Proehl director
John Geltosky director 685 ROUTE 202/206, BRIDGEWATER NJ 08807
Joseph L Turner director 10505 ROSELLE STREET, SAN DIEGO CA 92121
Joseph Lewis 10 percent owner PO BOX N7776, LYFORD BAHAMAS
Boxer Asset Management Inc. 10 percent owner CAY HOUSE, EP TAYLOR DRIVE N7776, LYFORD CAY, NEW PROVIDENCE C5 00000
Boxer Capital, Llc 10 percent owner 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Mva Investors, Llc 10 percent owner 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
William R Rohn director PO BOX 676367, RANCHO SANTA FE CA 92067